including phosphorylation of IκBα at two sites by a specific IκBα kinase (6, 18) of the SCF1 family, which then leads to ubiquitination of the phosphorylated IκBα by a specific E3 enzyme complex (19) (20) (21) (22) (23) ; this in turn allows binding to valosin-containing protein (VCP) (24) , which appears to provide a physical link between the ubiquitinated IκBα and the 26S proteasome.
PR39 is a highly basic arginine/proline-rich peptide originally isolated from porcine intestine on the basis of its antibacterial activity (25) . The peptide is secreted in a preproprotein form that includes a canonical leader sequence and rapidly undergoes cleavage of the NH 2 -terminal portion to generate the mature form composed of the 39 COOH-terminal amino acids (26) . Whereas the sequence of the NH 2 -terminal part of the preproprotein is highly homologous to the cathelin gene family members, the sequence of the 39 COOHterminal amino acids that make up the mature peptide has no homology to any other known protein (26) . PR39 can rapidly cross cell membranes and, by virtue of its proline-rich composition, may interact with SH3 domains of p47 phox (27) and p130 Cas (28) . The peptide, predominantly produced by blood-derived macrophages (29, 30) , is found at the sites of active inflammation, including skin wounds and myocardial infarction, and may play an important role by inducing expression of heparan sulfate-carrying core proteins, syndecan 1 and 4 (30, 31) , and inhibiting degradation of the hypoxia-inducible factor-1α (HIF-1α) protein (32) . However, the molecular events involved in this peptide's actions remain largely unknown.
The present study was undertaken to explore the molecular mechanisms of PR39 activity. We show that the peptide binds to the α7 subunit of the 20S proteasome and can block degradation of IκBα by the Ubproteasome pathway without disrupting overall proteasome activity and suppress NF-κB-dependent gene expression both in cell culture and in two different models of acute injury in mice.
Methods
Cell lines, supplies, and reagents ECV304 cells were cultured in M199 medium supplemented with 10% FBS. Human umbilical vein endothelial cells (HUVEC; Clonetics Inc., Walkersville, Maryland, USA) were cultured in DMEM supplemented with 20% FBS. U937 cells (courtesy of J. Chang, Beth Israel Deaconess Medical Center) were cultured in RPM-1640 medium supplemented with 10% FBS. A mixture of 100 µg/mL penicillin/streptomycin was added to all cultures. For stable transfection, a fulllength porcine PR39 cDNA (containing the leader sequence) and a cDNA construct corresponding to the fourth exon of the porcine PR39 gene were cloned into the eukaryotic expression vector pGRE5-2 and used to stably transfect ECV304 as described previously (32) .
Synthetic PR39 peptide was generated on the basis of porcine sequence (26) and purified by HPLC (Genemed Synthesis Inc., South San Francisco, California, USA). Lactacystin and MG132 were obtained from Calbiochem-Novabiochem Corp. (San Diego, California, USA) and hrTNF-α from Sigma Chemical Co. (St. Louis, Missouri, USA).
Coimmunoprecipitation
For coimmunoprecipitation, transfected cells, wild-type ECV, full-length PR39 (ECV-PR39), and exon 4 PR39 (ECV-E4), were lysed with the RIPA buffer, and equal amounts of total protein were precleared with nonimmune rabbit serum and protein G plus/protein Aagarose beads (Calbiochem-Novabiochem Corp.). The cleared samples were incubated at 4°C overnight with 20 µL of polyclonal anti-PR39 Ab (32) and 40 µL of protein G plus/protein A-agarose beads or with the beads alone. The beads were then washed three times with PBS, resuspended in Laemmli sample buffer (2% SDS, 10% glycerol, 0.5% β-mercaptoethanol, 0.004% bromphenol blue, 50 mM Tris-HCl, pH 6.8), resolved on 10% SDS-PAGE, transferred to PVDF membrane, and blotted with 1:1000 mouse monoclonal anti-α7 or anti-α2 Ab's (Affiniti Research Products Ltd., Exeter, United Kingdom). As a control, the total cell lysate of ECV cells was subjected to SDS-PAGE and immunoblotting with anti-α7 and anti-α2 Ab's.
Yeast two-hybrid screening
Two-hybrid screening was done using Clontech MATCHMAKER GAL4 System 2 (Clontech Laboratories, Palo Alto, California, USA). The cDNA of porcine PR39 peptide corresponding to the fourth exon (amino acids 131 to 169) was subcloned into pAS2-1 vector as bait. Mouse embryo 3T3 MATCH-MAKER cDNA library (Clontech Laboratories) was screened in the yeast Y190 strain. Plasmids from HIS3/LacZ positive clones were sequenced and cotransformed with bait plasmid back into the Y190 strain to confirm the interaction.
IκBα ubiquitination studies
In vitro assay. IκBα and its phosphorylation-site mutants 32 S→ 32 A and 36 S→ 36 A (S32A-IκBα and S36A-IκBα) in pBluescript plasmids were generously provided by T. Maniatis (Harvard University, Boston, Massachusetts, USA). Plasmid for the overproduction of GST-Ub (pGEX-2TK-Ub) was a gift of J. Huibregtse (Rutgers University, Piscataway, New Jersey, USA). GST-Ub was prepared as described (33) .
Preparation of HeLa cell extract. HeLa cells were harvested by centrifugation at 500 g. The packed cell volume was estimated and the cells osmotically lysed by the addition of 5 volumes of hypotonic buffer (10 mM TrisCl, pH 7.9, 1.5 mM MgCl 2 ,10 mM KCl, 0.2 mM PMSF, 0.5 mM DTT). The mixture was incubated on ice for 10 minutes, then homogenized with 12 strokes of a Dounce homogenizer (B-type pestle). The crude lysate was centrifuged for 15 minutes at 500 g, followed by recentrifugation of the supernatant at 100,000 g for 30 minutes. This supernatant was concentrated by the addition of solid (NH 4 ) 2 SO 4 to 80% saturation, stirred at 4°C for 30 minutes, and centrifuged for 15 minutes at 21,000 g. The precipitate was resuspended in 1:5 volume of 20 mM Tris-Cl, pH 7.6, 20 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 0.5 mM PMSF, 50 µM chymostatin, and 20 µM E64, and dialyzed against more than 500 volumes of 20 mM Tris-Cl, pH 7.6, 20 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 10% glycerol at 4°C overnight, and stored at -70°C until use.
Ubiquitination assay. 35 S-IκBα and 35 S-S32A/S36A IκBα were prepared by coupled in vitro transcription/translation in wheat germ extract (Promega, Madison, Wisconsin, USA) using Tran 35 S-Label (ICN Radiochemicals, Costa Mesa, California, USA) according to the manufacturer's instructions. 35 S-IκBα and 35 S-S32A/S36A IκBα were removed from unincorporated radioactivity by gel filtration using a NICK-Spin column (Pharmacia Biotech, Piscataway, New Jersey, USA). 35 S-IκBα or 35 S-S32A/S36A IκBα (∼40,000 cpm) were added to a 20-µL reaction containing 2 mM ATP, 10 mM creatine phosphate, 0.2 mg/mL creatine kinase, 70 µM GST-ubiquitin, 3.3 µM okadaic acid (Sigma Chemical Co.), 30 µM MG132, 2 µM ubiquitin aldehyde, 200 µM bestatin, 10 µM E64, 0.5 mM PMSF, and 80 µg HeLa cell extract in 20 mM Tris-Cl, pH 7.6, 20 mM KCl, 10 mM MgCl 2 , 1 mM DTT, 10% glycerol. PR39 or control peptides were also added to individual reactions. The samples were incubated at 37°C for 90 minutes followed by the addition of Laemmli sample buffer to stop the conjugation reactions. The samples were then heated for 5 minutes at 95°C and analyzed by SDS-PAGE on 4-15% acrylamide gradient gels (BioRad, Hercules, California, USA). After electrophoresis, the gels were incubated with gentle stirring in 30% methanol, 10% acetic acid, dried, and analyzed using a Fuji PhosphoImager (Fuji, Tokyo, Japan).
Cell-culture assay. ECV304 cells were stably transfected with a HA-tagged ubiquitin plasmid MT123 (kind gift of G. Walz, Beth Israel Deaconess Medical Center). The clone with the highest expression of HA-ubiquitin was treated with 10 µM PR39 for 45 minutes followed by treatment with 1 ng/mL TNF-α for 20 minutes. At that point, the cells were washed and lysed and IκBα was immunoprecipitated. After SDS-PAGE and membrane transfer of the immunoprecipitated material, the HAubiquitinated IκBα was visualized by Western blotting with an anti-HA Ab (Santa Cruz Biotechnology, Santa Cruz, California, USA).
Transcription assays
Stable cell lines expressing luciferase reporter gene under control of a tandem of four NF-κB-binding sites in front of a minimal TK promoter (NF-κB-TK-Luc, courtesy of G. Walz) or a cytomegalovirus (CMV) promoter (CMV-Luc, pRLCMV; Promega) were generated by electroporation of ECV304 cells followed by selection in 1 mg/mL G418-supplemented media (GIBCO-BRL Life Technologies, Gaithersburg, Maryland, USA)as described previously (34) . Twenty to 30 clones expressing each construct were pooled for subsequent assay. Following cell lysis, luciferase activity was determined using Luciferase Assay System (Promega) (34) .
Protein-degradation assay
Exponentially proliferating U937 cells were grown in 10% FBS-RPMI-1640 methionine-free medium supplemented with 200 µCi 35 S methionine for 16 hours. Cells were then washed with complete RPMI-1640 medium three times and cultured in 10% FBS-RPMI (chase) in the presence of 10 µM of either PR39 or MG132 or an equal volume of PBS. Chloroquine (45 µM) was added to all cultures to prevent lysosomal protein degradation. One hour later the cells were lysed, and TCA-soluble 35 S counts were measured in a liquid scintillation counter (Beckman Instruments Inc., Fullerton, California, USA). All experiments were carried out in triplicate and repeated three times.
Electrophoretic mobility shift assay
Nuclear extracts were prepared as described (35) . In brief, pancreatic tissue was homogenized in ice-cold 0.3 M sucrose, cells were subjected to iso-osmolar lysis in buffer containing NP-40, and the nuclei were isolated. Nuclear protein was extracted from intact nuclei in a buffer containing 0.4 M KCl and stored at -70°C before analysis.
Aliquots of 7.5-10 µg of nuclear protein were mixed in 25-µL reactions containing 5 mM Tris, pH 7.5, 100 mM NaCl, 1 mM DDT, 1 mM EDTA, 4% (vol/vol) glycerol, 0.08 mg/mL salmon sperm DNA, and H 2 O. The oligonucleotide probe (5′-AGT TGA GGG GAC TTT CCC AGG C-3′; Promega) containing the κB-binding motif was end-labeled with [γ-32 P]ATP using T 4 polynucleotide kinase. Then, 10 6 cpm of the probe was added to the mixture, and the binding reaction was allowed to proceed for 20 minutes at room temperature. The unlabeled oligonucleotide was used in the specific competition assay. DNA-protein complexes were resolved in a 6% nondenaturing polyacrylamide gel in a Trisborate-EDTA buffer at 150 V. Gels were dried and exposed to Kodak Bio Max MR film (Eastman Kodak Co., Rochester, New York, USA) at -70°C.
Mouse acute injury models
Acute pancreatitis. Male mice weighing 20-25 g (ICR; Charles River Laboratories, Wilmington, Massachusetts, USA) were pretreated with PR39 (10 mg/kg, intravenously) or physiological saline 1 hour before injecting 50 µg/kg caerulein intraperitoneally (Research Plus, Bayonne, New Jersey, USA) to induce acute pancreatitis (36) . Thirty minutes later the animals were sacrificed in a CO 2 chamber and a 75-100 mg piece of pancreas was removed for Western blotting and NF-κB gel-shift assays.
Acute myocardial infarction. Transgenic mice stably expressing PR39 in cardiac myocytes (αMHC-PR39 mice) and littermate controls (both op/op strain background), or C57BL/6 mice were subjected to acute coronary artery ligation as described (30) . C57BL/6 mice were randomized to intraperitoneal implantation of Alzet Minipumps (Alza Corp., Palo Alto, California, USA) delivering 1 µg/kg/24 h of PR39 or buffer. Myocardial tissues collected 1, 3, or 7 days later from αMHC-PR39 and littermate control mice were subjected to Western blot analyses for VCAM-1 gene expression, which was normalized to expression levels before induction of infarction. Infarct size was determined from serial cross-sections of myocardial tissues after sacrifice at day 7 using digital camera and quantitative image analysis software (Optimas 6.0, Media Cybernetics, Silver Spring, Maryland, USA).
Results
To identify possible intracellular targets of PR39 action, we carried out a yeast two-hybrid screen of a mouse cDNA library using the unique fourth-exon DNA sequence of porcine PR39 gene as bait. Four clones growing on selective media and demonstrating lacZ staining were purified and sequenced. All four encoded overlapping, identical cDNA sequences, which are highly homologous to the sequence of the human α7 (HC8) subunit of the 20S proteasome (GeneBank accession no. AF055983). Deletion analysis showed that the presence of both the COOH-terminal as well as the NH 2 -terminal sequences of α7 are required for PR39 binding (Figure 1a ). To confirm that PR39 and
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The To further confirm PR39-α7 interaction, we performed Western blotting of ECV-PR39-cell immunoprecipitate obtained with an anti-α7 Ab or a nonimmune IgG with an anti-PR39 Ab. In this experiment, the band corresponding to the PR39 peptide was present only in the anti-α7, but not control, immunoprecipitate (Figure 1c ). Taken together, these results suggest that PR39 can bind to the 20S proteasome particle through an interaction with the α7 subunit.
Since such an interaction with a proteasome subunit may result in inhibition of proteasome-mediated protein degradation, we assessed the effect of PR39 expression on the degradation of IκBα, an important regulator of gene transcription. Stable expression of PR39 construct in ECV304 cells resulted in increased levels of IκBα (Figure 1d, compare lanes 1 and 2) . The same increase in IκBα protein levels was seen after exposure of ECV304 cells to proteasome-specific inhibitor lactacystin or synthetic PR39 peptide (Figure 1d, lanes 3 and 4) .
TNF-α induces rapid degradation of IκBα by the Ubproteasome pathway (16) . We therefore tested the ability of PR39 to inhibit TNF-α-induced degradation of IκBα in U937 cells that normally exhibit significant baseline levels of IκBα (37) . TNF-α caused a rapid decline of the level of IκBα in these cells, and this effect was markedly reduced by pretreatment with PR39 or proteasome inhibitors lactacystin or MG132 ( Figure  1e ). To test whether treatment with PR39 irreversibly blocked IκBα degradation, U937 cells were pretreated with the peptide and then were extensively washed, and 45 minutes later were exposed to TNF-α. In parallel, U937 cells were exposed to MG132, a rapidly reversible competitive inhibitor of the proteasome, or with lactacystin, which covalently and irreversibly modifies the active-site threonine residues. Western blot analysis demonstrated the complete disappearance of IκBα protein in PR39 and MG132-treated cells, whereas pretreatment with lactacystin irreversibly blocked proteasome-mediated degradation of IκBα (Figure 1f) , suggesting that PR39 effect, like that of MG132, is reversible. To further study the time course of PR39-mediated inhibition of TNF-α-induced degradation of IκBα, primary HUVEC cells were pretreated with PR39 for a variable period of time before TNF-α administration. Whereas as little as 10 minutes of pretreatment was sufficient to partially block TNF-α-induced IκBα degradation, full protection was seen after 60 minutes of pretreatment, and the effect was lost if TNF-α administration was delayed for more than 2 hours after exposure to PR39 (Figure 1g ). These results further support the notion that PR39 has a transient and reversible effect on TNF-α-induced IκBα degradation.
To show that the PR39 not only prevented inhibition of IκBα degradation but also inhibited NF-κB-dependent transcription (i.e., to show that the IκBα protein is
The fully functional), we employed pooled stable ECV304 clones expressing a luciferase reporter construct under control of either NF-κB-TK or CMV promoters. Stimulation with TNF-α of NF-κB-TK-Luc-expressing cells induced a 15.8-fold increase in the luciferase activity that was almost completely inhibited by pretreatment with either PR39 or MG132 (Figure 2, a and b) . At the same time, PR39 or MG132 had no effect on the luciferase activity in cells expressing CMV-Luc construct.
To study whether PR39 can also inhibit NF-κB-dependent transcription in animals, we examined IκBα protein levels and the presence of NF-κB transcriptional activity in a model of acute pancreatitis. In this model, induction of acute pancreatitis by treatment with the cholecystokinin analogue caerulein (36) leads to the prompt disappearance of IκBα (Figure 2c ) and activation of NF-κB-dependent transcription in the pancreas (Figure 2d ). Intravenous injection of 10 mg/kg of PR39 1 hour before caerulein administration largely prevented IκBα degradation and, consequently, NF-κB-dependent gene expression as assessed by DNA gel shifts (Figure 2, c and d) .
To examine the functional consequences of PR39-mediated inhibition of NF-κB-dependent gene expression, we evaluated the effect of peptide administration on expression of NF-κB-dependent adhesion proteins VCAM-1 and ICAM-1 in cell culture and in the setting of acute myocardial infarction in mice. Exposure of HUVEC to TNF-α in culture (38) or induction of ischemia in the heart (39) leads to increased VCAM-1 and ICAM-1 gene expression, which is thought to play a major role in mediation of postischemic myocardial injury (40) . However, pretreatment with PR39 prevented TNF-α-induced induction of expression of both adhesion proteins in HUVEC cells (Figure 3a) .
To study this in vivo, we assessed VCAM-1 and ICAM-1 protein levels after induction of myocardial infarction in transgenic mice expressing PR39 cDNA in cardiac myocytes (αMHC-PR39) (32) or age-and strainmatched control mice. The αMHC-PR39 mice express PR39 peptide selectively in cardiac myocytes, and the peptide expression is not associated with any detectable changes in any baseline heart morphometric or physiologic parameters (weight, wall thickness, left-ventricular function), except for increased vascularity (32) .
Coronary ligation in control (wild-type C57BL/6) mice led to a significant rise in the VCAM-1 and ICAM-1 expression by 24 hours, reached a peak by 72 hours, and then gradually declined. In contrast, induction of myocardial infarction had no effect on VCAM-1 or ICAM-1 expression in α-MHC-PR39 mice (Figure 3b ). Morphometric evaluation of the infarct size in these mice 7 days after coronary ligation showed a significantly smaller area of necrosis in αMHC-PR39 (n = 6) compared with control animals (n = 8; Figure 3c ). To test whether exogenously administered peptide would have a similar effect on myocardial infarct size, C57BL/6 mice were randomized to sustained 7-day intraperitoneal infusion of PR39 peptide (1 µg/kg/day; n = 6) or saline control (n = 13) via an implantable osmotic pump immediately after coronary ligation. Morphometric assessment of the infarct size at day 7 demonstrated significantly smaller infarcts in PR39-treated, compared with saline-treated, mice (Figure 3d) .
One possible explanation of the PR39-dependent inhibition of IκBα degradation would be that the peptide, like MG132, reversibly inhibits all proteasome function, thus generally suppresses intracellular protein degradation. Therefore, we compared the extent of degradation of long-lived cell proteins before or after exposure to either PR39 or MG132. After 16-hour metabolic labeling of total cell protein in ECV304 cells, MG132 treatment resulted in approximately 50% inhibition of total cellular protein degradation, in accordance with results reported previously (41) . In contrast, administration of PR39 had little or no effect on this process (Figure 4a ). To confirm that PR39 does not cause a general inhibition of protein degradation, we studied the expression level of HSP-70, a major heat shock protein whose expression is stimulated
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The by proteasome inhibitors (37, 41, 42) . Western blot analysis demonstrated a striking increase in HSP-70 levels in cultured ECV304 cells after treatment with 10 µM of MG132. However, exposure to a similar concentration of PR39 failed to stimulate HSP-70 accumulation ( Figure  4b ). In addition, studies in HUVEC and ECV304 cells with specific antibodies failed to demonstrate any effect of PR39 treatment on the levels of two cell-cycle proteins principally controlled by proteasome-dependent degradation -the cell-cycle inhibitor p21 Cip1/Waf1 and the transcription factor c-Fos (Figure 4c) . Prolonged exposures to proteasome inhibitors tend to induce apoptosis in cell culture (43) . To assess the potential cytotoxicity of PR39, ECV304 cells were cultured in the presence of 10 µM of PR39, MG132, or lactacystin. Cell counts 48 hours later documented that, while addition of PR39 did not affect the cells' ability to proliferate, exposure to either MG132 or lactacystin led to a significant decline in cell counts (Figure 4d ). These results demonstrate that PR39 is able to inhibit IκBα degradation without significantly affecting overall protein degradation in cells.
The preceding experiments suggest that PR39 inhibits IκBα degradation in a relatively selective manner. To explore potential mechanisms of this inhibition, we studied the effect of peptide administration on IκBα phosphorylation and ubiquitination. TNF-α treatment leads to phosphorylation of IκBα, which is required for its subsequent ubiquitination. Western blotting of U937 cell lysates after in vivo 32 P labeling demonstrated the appearance of the phosphorylated form of IκBα after TNF-α exposure. Pretreatment with PR39 increased the amount of the phosphorylated form of IκBα, presumably due to inhibition of its degradation (Figure 5a) . To test the effect of PR39 on IκBα ubiquitination in a cell-free system, HeLa cell extract was used to ubiquitinate in vitro transcribed, translated, and phosphorylated IκBα. In the absence of PR39, incubation of phosphorylated IκBα protein with a HeLa extract led to the appearance of multiple highmolecular-weight ubiquitinated forms of IκBα. The addition of PR39 in an amount sufficient to inhibit IκBα degradation in cell culture had no effect on the extent of IκBα ubiquitination in this assay (Figure 5b) .
To assess the effect of PR39 treatment on IκBα ubiquitination in intact cells, we generated a stable ECV304-derived cell line expressing HA-tagged ubiquitin. Immunoprecipitation of IκBα followed by Western blotting with anti-HA Ab demonstrated the accumulation of more ubiquitinated IκBα complexes in cells pretreated with 10 µM of PR39 than in untreated cells (Figure 5c ). Together these findings argue that PR39 does not block the ubiquitination process, but does inhibit the degradation of ubiquitinated IκBα by the 26S proteasome.
A recent study suggested that binding of the ubiquitinated IκBα to VCP, a 26S proteasome-associated protein, is necessary, but not sufficient, for subsequent IκBα degradation (24) . Western blotting with the anti-VCP Ab demonstrated the presence of this protein in the anti-PR39 Ab immunoprecipitate of the ECV-PR39 cells (not shown). Western blot analysis of anti-IκBα Ab immunoprecipitated material from ECV304 cells demonstrated the presence of VCP in accord with the study reported previously (24) . Pretreatment with PR39 increased the amount of VCP in the IκBα immunoprecipitate (Figure 5d ), as would be expected given increased amount of ubiquitinated forms of IκBα in the PR39-treated cells. We conclude from these studies that PR39 does not interfere with IκBα-VCP binding.
Discussion
In this study we have presented several types of evidence that the naturally occurring antibacterial 39-amino acid peptide, PR39, inhibits IκBα degradation in cultured cells and in two different mice models and that functional effects of PR39 treatment is mediated by inhibition of NF-κB-dependent gene expression. Sever al lines of evidence support this conclusion. In cell culture the peptide inhibited TNF-α-induced activation of NF-κB-TK-promoter expression and induction of ICAM-1 and VCAM-1 expression in HUVEC cells. In mice studies, the peptide blocked NF-κB-dependent transcription in the setting of acute pancreatitis and prevented increase in ICAM-1 and VCAM-1 expression after induction of acute myocardial infarction. The later model was used to assess the functional significance of PR39 activity. Recent studies have documented that the ischemia-reperfusion is associated with TNF-α release from the heart (44, 45) , which is associated with early induction of NF-κB gene expression (39) . This, in turn, is associated with increased expression of adhesion molecules including ICAM and VCAM (46, 47) , which can be blocked by proteasome inhibitors (47) or other compounds capable of inhibiting NF-κB activity (40) . Furthermore, inhibition of proteasome-mediated IκBα degradation (48) or adhesion molecule expression has been shown to reduce significantly ischemia-reperfusion injury (49) (50) (51) .
The link between PR39, inhibition of IκBα degradation, inhibition of NF-κB-dependent transcription, fall in ICAM-1 and VCAM-1 gene expression, and reduction in the size of myocardial infarction does not rule out that PR39 may have other biological effects. Indeed, we have shown that the peptide increases HIF-1α protein levels (32) , and others have reported PR39 interactions with p47 phox (27) and p130 Cas (28) .
Whereas the ability to inhibit IκBα degradation may suggest that PR39 acts as a proteasome inhibitor, several observations clearly set it apart from the smallmolecule proteasome inhibitors described to date. Most important in this regard is the relatively selective nature of the PR39 effect. This selectivity is indicated by the lack of any effect on overall proteasomedependent protein degradation in cells as well as degradation of two cell-cycle genes known to be regulated by proteasome-dependent degradation -the cell cycle inhibitor p21 Cip1/Waf1 (52) and a transcription factor c-fos (53) . Additional evidence in favor of selective inhibition of proteasome activity by PR39 includes the absence of induction of heat shock proteins such as HSP-70 and the lack of toxicity after a long-term exposure in cell culture or transgenic expression in mice.
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The In contrast, exposure of cultured cells to proteasome inhibitors MG132 and lactacystin leads to a general reduction in intracellular proteolysis, a rapid increase in HSP-70 expression, and cell death (37, 41, 42) . In this regard it is interesting to note that the lack of PR39 effect on cell proliferation in culture is consistent with the lack of increase in p21 Cip1/Waf1 expression seen with proteasome inhibitors such as MG132, which leads to inhibition of cell growth (54) .
Whereas known inhibitors of 20S proteasome such as lactacystin and MG132 affect its active sites, and therefore the inhibition of proteolysis is not specific to any particular protein or class of proteins, selective inhibition of proteasome-mediated degradation potentially can be achieved by blocking substrate-specific steps in the degradative pathway. We therefore carried out experiments to determine whether the inhibition of IκBα degradation by PR39 is due to inhibition of known steps required for its proteasome-mediated degradation, including phosphorylation, ubiquitination, and VCP binding.
Studies in the cell-free system failed to show any effect of PR39 treatment on ubiquitination of IκBα, whereas cell-culture experiments demonstrated an accumulation of phosphorylated and ubiquitinated forms of IκBα in the PR39-treated cells. Recently, it was shown that proteasome-dependent degradation of IκBα requires its binding to a cytoplasmic protein, VCP, that may provide a physical link between the ubiquitinated IκBα and the 26S proteasome (24) . In our experiments, exposure of cells to PR39 did not interfere with IκBα-VCP binding, as demonstrated by the presence of the VCP band on the immunoprecipitate of whole-cell lysate with anti-IκBα Ab in the presence or absence of PR39. Thus, PR39 did not interfere with any of the known steps involved in proteasomemediated degradation of IκBα.
Several experimental results in this study are consistent with direct interaction of PR39 with the 20S particle. The peptide is able to bind with high affinity directly to the α7 subunit of the proteasome as shown in the yeast two-hybrid assay, as well as by coimmunoprecipitation with the anti-PR39 and anti-α7 Ab's. Furthermore, as a result of binding to α7, PR39 is able to bring down at least one other (α2) 20S subunit, and probably other 20S subunits as well, suggesting that the peptide binds to the whole 20S particle without causing its dissociation. Whereas the site of interaction on the α7 subunit or on PR39 has not been established, one possibility is the high negative charge of the COOH-terminal end of the α7 subunit, which makes it a likely site for binding of the positively charged PR39 molecule. The α7 COOH-terminal sequence is actually the most negatively charged sequence of any of the proteasomal α subunits, and it has the ability to assemble into heptameric ring structures by itself, as well as to induce ring formation of other α subunits (55) .
However, it is unclear how PR39 interaction with the 20S proteasome can lead to selective inhibition of the degradation of phosphorylated and ubiquitinated IκBα. One possible mechanism would include interference with binding of ubiquitinated IκBα-VCP complex to the 26S proteasome. The observed inhibition of the NF-κB-dependent transcription in PR39-treated cells or animals is consistent with this possibility, since inhibition of VCP-IκBα binding to the proteasome would leave the ubiquitinated IκBα in complex with NF-κB. Alternatively, PR39 may interfere with another, yet unknown, step involved in IκBα degradation by the proteasome. Finally, PR39 binding to the α7 subunit may alter the three-dimensional proteasome architecture or interaction of the 20S particle and the 19S regulatory subunit that would affect the entry of certain protein substrates into the 20S cylinder. All of these possibilities are consistent with the observation that PR39 inhibition of IκBα degradation is dose dependent and reversible, apparently requiring continuous presence of the peptide. It should be noted that this activity is not strictly limited to IκBα, since we have found that this peptide also inhibits proteasomedependent degradation of HIF-1α (32) . This could imply that the peptide affects a step common to degradation of these two proteins.
Several proteins interacting with subunits of 20S proteasome have been identified to date, including viral proteins Hbx (56), Tat (57) , and Tax (58) . For example, Tax binding to HC9 has been reported to facilitate binding of p105 NF-κB to the proteasome and accelerates its proteolytic maturation (58) . Thus, PR39 is yet another example of α subunit-binding protein that may have a unique regulatory activity of the 26S complex.
In conclusion, the ability of PR39 peptide to block stimulation of NF-κB-dependent gene expression relatively selectively in animal models of pancreatitis and acute myocardial infarction may have important implications as a potential therapeutic approach to management of a number of disease states, including acute inflammation, immune and autoimmune responses, and ischemia-reperfusion injury.
